More MS news articles for Jan 2002

Anti-S-Nitrosocysteine Antibodies Are a Predictive Marker for Demyelination in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11756495&dopt=Abstract

J Neurosci 2002 Jan 1;22(1):123-132
Boullerne AI, Rodriguez JJ, Touil T, Brochet B, Schmidt S, Abrous ND, Le Moal M, Pua JR, Jensen MA, Mayo W, Arnason BG, Petry KG.
Department of Neurology, University of Chicago, Chicago, Illinois 60637, Institut National de la Sante et de la Recherche Medicale, Unite 259, and Laboratory of Neurobiologie des Affections de la Myeline EA2966, Victor Segalen Bordeaux II University, 33076 Bordeaux, France, and Department of Neurology, University of Bonn, 53105 Bonn, Germany.

Multiple sclerosis (MS) is characterized by inflammation within the CNS.

This inflammatory response is associated with production of nitric oxide (NO) and NO-related species that nitrosylate thiols.

We postulated that MS patients would exhibit an antibody (Ab) response directed against proteins containing S-nitrosocysteine (SNO-cysteine) and showed that anti-NO-cysteine Abs of the IgM isotype are in fact present in the sera of some MS patients (Boullerne et al., 1995).

We report here the presence of a seemingly identical Ab response directed against SNO-cysteine in an acute model of MS, experimental autoimmune encephalomyelitis (EAE) induced in Lewis rats with the 68-84 peptide of guinea pig myelin basic protein (MBP(68-84)).

Serum levels of anti-SNO-cysteine Abs peaked 1 week before the onset of clinical signs and well before the appearance of anti-MBP(68-84) Abs.

The anti-SNO-cysteine Ab peak titer correlated with the extent of subsequent CNS demyelination, suggesting a link between Ab level and CNS lesion formation.

In relapsing-remitting MS patients, we found elevated anti-SNO-cysteine Ab at times of relapse and normal values in most patients judged to be in remission.

Two-thirds of patients with secondary progressive MS had elevated anti-SNO-cysteine Ab levels, including those receiving interferon beta-1b.

The data show that a rise in circulating anti-SNO-cysteine Ab levels precedes onset of EAE.

Anti-SNO-cysteine Abs are also elevated at times of MS attacks and in progressive disease, suggesting a possible role for these Abs, measurable in blood, as a biological marker for clinical activity.
 

PMID: 11756495 [PubMed - as supplied by publisher]